(Press-News.org) In a phase 2 clinical trial of the immune checkpoint inhibitor pembrolizumab, investigators found that 42 percent of patients with metastatic brain cancer benefited from the therapy, with seven patients in the trial surviving longer than two years. The authors caution that these benefits must be weighed against risk of toxicity, but, overall, the study shows promising results that warrant larger studies and efforts to identify patients most likely to benefit from this treatment. Their findings are published in Nature Medicine and presented simultaneously at the 2023 ASCO Annual Meeting on June 2.
“There are very few effective treatments for patients with brain metastases. Our overarching objective is to find improved therapies for this patient population,” said corresponding author Priscilla K. Brastianos, MD, of the Mass General Cancer Center. “With this trial, we investigated pembrolizumab, which is an immunotherapy for patients with brain metastases. We showed that pembrolizumab was tolerated and showed clinical benefit in the brain in 42 percent of patients, which is promising for this patient population.”
The single-arm, open-label, phase 2 trial, funded in part by Merck Sharp & Dohme, a subsidiary of Merck & Co, the manufacturer of pembrolizumab, included nine patients with previously untreated, asymptomatic brain metastases (cohort A) and 48 patients with recurrent and progressive disease after prior therapy (cohort B). Participants were enrolled in the trial between Oct. 6, 2016 and Oct. 16, 2018. The primary endpoint of the study was response rate, including complete response, partial response, or stable disease. Patients in the trial had primary tumor diagnoses that included breast, melanoma, non-small cell lung, small-cell lung, pituitary, and other cancers.
The research team found that 24 of the 57 patients had an intracranial benefit, with five patients experiencing a complete or partial response to treatment. This included three patients in cohort A and 21 in cohort B, meaning the study achieved its primary endpoint.
The team also reported that median overall survival for participants was 8 months. While the study did not have a control arm, previous studies have estimated overall survival for patients with brain metastases to be 4-6 months. Seven patients in the study experienced prolonged overall survival of two or more years, including five patients with primary breast cancer, one patient with primary melanoma and one patient with primary sarcoma.
The team also examined safety and tolerability. Five patients discontinued treatment due to toxicity, and 50 of the 57 patients had one more adverse event. The most frequent adverse events were fatigue, nausea, headache, vomiting and transaminitis (elevated levels of liver enzymes in the blood).
As next steps, the research team recommends investigating biomarkers of response, especially among the study’s “exceptional responders,” that may help to predict which patients are most likely to respond to therapy. The authors note that additional studies will be needed to identify specific facets to those patients’ tumors or tumor microenvironments that led to such a favorable response.
“Our study illustrates the promise of checkpoint inhibitors for future therapeutic strategies for brain metastases,” said Brastianos. “And our work suggests that the decision to give a checkpoint inhibitor should not be based solely on the primary tumor’s origin—it is likely that there are yet-to-be determined factors that may predict response. Future studies to identify these factors may help guide, inform, and personalize treatment for patients with brain metastases.”
Disclosures: Brastianos consulted for Tesaro, Angiochem, Genentech-Roche, ElevateBio, Eli Lilly, SK Life Sciences, Pfizer, Voyager Therapeutics, Sintetica, MPM, Advise Connect Inspire, Kazia and Dantari, received institutional research funding (to MGH) from Merck, Mirati, Eli Lilly, Kinnate, BMS and Pfizer and has received honoraria from Merck, Medscape, Pfizer, and Genentech-Roche. Additional disclosures for co-authors can be found in the Nature Medicine paper.
Funding: Funding for this trial was provided by Merck Sharp & Dohme, a subsidiary of Merck & Co., Damon Runyon Cancer Research Foundation, Ben and Catherine Ivy Foundation. Brastianos also receives support from Breast Cancer Research Foundation, Hellenic Women’s Club Demetra Fund, Terry and Jean de Gunzburg MGH Research Scholar Fund and the National Institutes of Health (1R01CA227156-01 and 1R01CA244975-01). Additional support from American Brain Tumor Association Basic Research Fellowship In Honor of P. Fabbri, the William G. Kaelin, Jr., Physician-Scientist Award of the Damon Runyon Cancer Research Foundation, American Association for Cancer Research Breast Cancer Research Fellowship and the American Society of Clinical Oncology Young Investigator Award and the National Cancer Institute (R01CA211238 and R01CA244975).
Paper cited: Brastianos, Priscilla et al. “Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results” Nature Medicine DOI: 10.1038/s41591-023-02392-7
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
The paper, published April 17 in The Lancet Regional Health – Americas, was co-authored by Dr. Gunisha Kaur, an associate professor of anesthesiology at Weill Cornell Medicine and medical director of the Weill Cornell Center for Human Rights; Stephen Yale-Loehr, a professor of immigration law practice at Cornell Law School; and Jin K. Park, a medical student at the Harvard School of Medicine and the first DACA recipient awarded a Rhodes Scholarship.
“The erratic enforcement of the DACA program since its inception has led many immigrants and their families to disengage completely from the healthcare system to avoid risking deportation,” said ...
Researchers at the University of Louisville have received $5.8 million in two grants from the National Institutes of Health to expand their work to better understand and prevent immune system dysregulation responsible for acute respiratory distress, the condition responsible for serious illness and death in some COVID-19 patients. A separate $306,000 NIH Small Business Innovation Research grant supports early testing of a compound developed at UofL as a potential treatment.
The three grants combined total $6.1 million.
During the pandemic, health care providers worked tirelessly to treat patients ...
WASHINGTON --- Research conducted at Georgetown University’s Lombardi Comprehensive Cancer Center and the Washington DC VA Medical Center on a database of veterans exposed to Agent Orange found an association for an increased risk of developing myeloproliferative neoplasms (MPNs), which are acquired stem cell disorders that can lead to overproduction of mature blood cells complicated by an increased risk of blood clots in arteries and veins. When MPNs progress, they can become deadly leukemias.
The findings will be presented at the American Society of Clinical Oncology 2023 annual meeting in Chicago in June.
Agent Orange is an herbicide that was utilized by the United States military ...
The US Food and Drug Administration (FDA) mandated folic acid fortification of all enriched cereal grains in 1996, and this regulation resulted in a reduction of neural tube defect (NTD)–affected pregnancies for the population in the United States. While this mandatory food fortification strategy is an example of a public health success, Hispanic women in the US continued to be twice as likely to give birth to a child affected by NTD compared to non-Hispanic women. It was not until the year 2016 that the FDA approved voluntary, but not mandatory, folic acid fortification for corn masa flour products in the US to focus on the Hispanic diet staples, such ...
Usually, the two characterizations of a material are mutually exclusive: something is either stiff, or it can absorb vibrations well – but rarely both. However, if we could make materials that are both stiff and good at absorbing vibrations, there would be a whole host of potential applications, from design at the nano-scale to aerospace engineering.
Buckling does the trick
A team of researchers from the University of Amsterdam has now found a way to create materials that are stiff, but still good at absorbing vibrations – and equally importantly, that can be kept very light-weight. David Dykstra, lead author of the ...
NEW YORK, N.Y. — June 2. Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through the Lupus Clinical Investigators Network (LuCIN) at top academic centers throughout North America.
Lupus is a devastating heterogeneous autoimmune disease affecting millions worldwide with symptoms that can range from debilitating fatigue to ...
About The Study: In this randomized crossover trial of autistic children, using a sensory-adapted dental environment was safe and efficacious in decreasing physiological and behavioral distress during dental care. This is important because enhancing oral care is critical for autistic children; this intervention may also be beneficial for populations beyond autism.
Authors: Leah I. Stein Duker, Ph.D., O.T.R./L., of the University of Southern California in Los Angeles, is the corresponding author.
To access the embargoed study: Visit our For The Media website ...
About The Study: This qualitative study found that participants perceived widespread and increasing use of algorithms in health care and lack of oversight, potentially exacerbating racial and ethnic inequities. Increasing awareness for clinicians and patients and standardized, transparent approaches for algorithm development and implementation may be needed to address racial and ethnic biases related to algorithms.
Authors: Peter Treitler, M.S.W., of Rutgers University in New Brunswick, New Jersey, is the corresponding author.
To ...
Contrary to expectations, the risk for relapses, overdoses and deaths related to substance use disorder didn’t increase after a large-scale prison release in New Jersey, according to a Rutgers study.
The study, published in JAMA Health Forum, examined whether post-release overdose deaths and drug-related hospital and emergency department visits increased after more than 2,000 individuals were released from prison in late 2020 as the result of a pandemic-era policy.
“Risk of relapse and adverse health events is high following prison release, with risk of fatal overdose ...
Our skin contains specialised long-lived killer cells that protect against intruders. Researchers at Karolinska Institutet in Sweden and the University of Copenhagen in Denmark have now identified how these cells are formed, and shown that high levels of memory killer cells in cancer tissue correlate with a better survival rate in people with melanoma. The study is published in the journal Immunity.
Certain immune T cells called tissue-resident memory cells are formed locally in the skin and other tissue, and protect against infections that they have encountered before. Some of ...
